EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Efficacy and Safety of Donidalorsen for Hereditary Angioedema

Marc A Riedl, Raffi Tachdjian, William R Lumry, Timothy Craig, Gül Karakaya, Asli Gelincik, Marcin Stobiecki, Joshua S Jacobs, Nihal M Gokmen, Avner Reshef, Mark M Gompels, Michael E Manning und 7 weitere

New England Journal of Medicine · 04.07.2024 · 391 (1) · 21-31

DOI: 10.1056/nejmoa2402478 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 04.07.2024. Verfasst von Marc A Riedl und 18 weiteren Autor:innen. Beteiligte Einrichtung: From the Division of Allergy and Immunology, University of California at San Diego, La Jolla (M.A.R.), the Division of Allergy, Immunology, and Rheum…. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Oligonucleotides, Antisense. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Ionis Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryOligonucleotides, AntisenseAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodInjections, SubcutaneousQuality of LifeChildOligonucleotides

Substanzen

Oligonucleotides, AntisensedonidalorsenOligonucleotides

Autor:innen und Institutionen

  • From the Division of Allergy and Immunology, University of California at San Diego, La Jolla (M.A.R.), the Division of Allergy, Immunology, and Rheumatology, University of California at Los Angeles, Los Angeles (R.T.),…

ORCID-Profile: Danny M Cohn

Förderung

  • Ionis Pharmaceuticals

Zitieren

APA

Riedl, M. A., Tachdjian, R., Lumry, W. R., Craig, T., Karakaya, G., Gelincik, A., Stobiecki, M., Jacobs, J. S., Gokmen, N. M., Reshef, A., Gompels, M. M., Manning, M. E., Bordone, L., Newman, K. B., Treadwell, S., Wang, S., Yarlas, A., Cohn, D. M., & OASIS-HAE Team (2024). Efficacy and Safety of Donidalorsen for Hereditary Angioedema. New England Journal of Medicine, 391(1), 21-31. https://doi.org/10.1056/nejmoa2402478

Vancouver

Riedl MA, Tachdjian R, Lumry WR, Craig T, Karakaya G, Gelincik A, et al. Efficacy and Safety of Donidalorsen for Hereditary Angioedema. New England Journal of Medicine. 2024;391(1):21-31. doi:10.1056/nejmoa2402478

BibTeX
@article{Riedl2024,
  author = {Riedl, Marc A and Tachdjian, Raffi and Lumry, William R and Craig, Timothy and Karakaya, Gül and Gelincik, Asli and Stobiecki, Marcin and Jacobs, Joshua S and Gokmen, Nihal M and Reshef, Avner and Gompels, Mark M and Manning, Michael E and Bordone, Laura and Newman, Kenneth B and Treadwell, Sabrina and Wang, Sophie and Yarlas, Aaron and Cohn, Danny M and OASIS-HAE Team, OASIS-HAE Team},
  title = {Efficacy and Safety of Donidalorsen for Hereditary Angioedema},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {1},
  pages = {21--31},
  doi = {10.1056/nejmoa2402478}
}
Kostenlos starten →